Towards government-funded special biomedical research programs to combat rare diseases in China

被引:7
作者
Chen, Kai [1 ]
Yao, Lan [1 ]
Liu, Zhiyong [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Med & Hlth Management, Wuhan 430030, Hubei, Peoples R China
关键词
Rare diseases; orphan drugs; public health; medical care; ORPHAN DRUGS;
D O I
10.5582/bst.2015.01048
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Rare diseases are rarely conditions that are often debilitating and even life-threatening, which was identified by the World Health Organization (WHO) with a prevalence of 0.65-1%. 5,000-7,000 rare diseases are thought to exist, which account for around 10% of diseases for individuals worldwide. It is estimated that over 10 million people were patients with rare disease in China. During the past years, public awareness of rare diseases has in fact heightened with the launching of campaigns by patients' organizations and spontaneous efforts by members of the public, not only in developed countries and regions including United States of America (USA), the European Union (EU), and in Japan, but also in China. However, the features of missed or delayed diagnosis, shortage of effective drugs, and the high cost of currently available drugs for rare diseases make it an important public health issue and a challenge to medical care worldwide. To combat rare disease, the government should assume the responsibility of taking on the important task of promoting the sustained development of a system of medical care for and research into rare diseases. Government-funded special biomedical research programs in the USA, EU, and Japan may serve as a reference for China coping with rare diseases. The government-funded special biomedical research programs consisting of leading clinicians and researchers to enhance basic and applied research on rare diseases were expected to be launched in China.
引用
收藏
页码:88 / 90
页数:3
相关论文
共 15 条
[1]  
[Anonymous], 2014, LANCET NEUROL, V13, P1061
[2]   Intraventricular Hemorrhage as an Unusual Presenting Form of Sneddon Syndrome [J].
Bayrakli, Fatih ;
Erkek, Emel ;
Kurtuncu, Murat ;
Ozgen, Serdar .
WORLD NEUROSURGERY, 2010, 73 (04) :411-413
[3]  
丁锦希, 2011, [中国药学杂志, Chinese Pharmaceutical Journal], V46, P1129
[4]   35 years of Japanese policy on rare diseases [J].
Hayashi, Shuichiro ;
Umeda, Tamami .
LANCET, 2008, 372 (9642) :889-890
[5]   Rare diseases and effective treatments: are we delivering? [J].
Luzzatto, Lucio ;
Hollak, Carla E. M. ;
Cox, Timothy M. ;
Schieppati, Arrigo ;
Licht, Christoph ;
Kaariainen, Helena ;
Merlini, Giampaolo ;
Schaefer, Franz ;
Simoens, Steven ;
Pani, Luca ;
Garattini, Silvio ;
Remuzzi, Giuseppe .
LANCET, 2015, 385 (9970) :750-752
[6]   Pricing for Orphan Drugs Will the Market Bear What Society Cannot? [J].
O'Sullivan, Brian P. ;
Orenstein, David M. ;
Milla, Carlos E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (13) :1343-1344
[7]   Market uptake of orphan drugs - a European analysis [J].
Picavet, E. ;
Annemans, L. ;
Cleemput, I. ;
Cassiman, D. ;
Simoens, S. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) :664-667
[8]   Rare diseases: what's next? [J].
Remuzzi, Giuseppe ;
Garattini, Silvio .
LANCET, 2008, 371 (9629) :1978-1979
[9]   Why rare diseases are an important medical and social issue [J].
Schieppati, Arrigo ;
Henter, Jan-Inge ;
Daina, Erica ;
Aperia, Anita .
LANCET, 2008, 371 (9629) :2039-2041
[10]   Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives [J].
Song, Peipei ;
Gao, Jianjun ;
Inagaki, Yoshinori ;
Kokudo, Norihiro ;
Tang, Wei .
INTRACTABLE & RARE DISEASES RESEARCH, 2012, 1 (01) :3-9